Literature DB >> 15200345

Management of fatigue in patients with multiple sclerosis.

Udo A Zifko1.   

Abstract

As long as no causal treatment is available for multiple sclerosis (MS), and as long as only some patients with MS respond to immunomodulators, symptomatic treatment is of paramount importance. Fatigue is the most common symptom of MS and is associated with a reduced quality of life. It is described as the worst symptom of their disease by 50-60% of patients. The first step in managing MS-related fatigue is identifying and eliminating any secondary causes. Primary fatigue syndrome can be alleviated with drug treatment in many cases. Modafinil has been shown to be effective in some studies, and amantadine is an alternative for patients who do not respond to or cannot tolerate modafinil. The nonpharmacological management of fatigue in MS includes inpatient rehabilitation and aerobic endurance exercise. This article describes the pathophysiology, diagnosis and treatment of MS-related fatigue--the most common symptom of MS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15200345     DOI: 10.2165/00003495-200464120-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  43 in total

1.  Modafinil for excessive daytime sleepiness in myotonic dystrophy.

Authors:  M S Damian; A Gerlach ; F Schmidt; E Lehmann ; H Reichmann
Journal:  Neurology       Date:  2001-03-27       Impact factor: 9.910

2.  Prospective study of neurorehabilitation in multiple sclerosis.

Authors:  D Kidd; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

3.  Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea.

Authors:  A I Pack; J E Black; J R Schwartz; J K Matheson
Journal:  Am J Respir Crit Care Med       Date:  2001-11-01       Impact factor: 21.405

4.  Fatigue in multiple sclerosis: relationship to depression, disability, and disease pattern.

Authors:  D C Kroencke; S G Lynch; D R Denney
Journal:  Mult Scler       Date:  2000-04       Impact factor: 6.312

5.  Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil.

Authors:  S Happe; W Pirker; C Sauter; G Klösch; J Zeitlhofer
Journal:  J Neurol       Date:  2001-07       Impact factor: 4.849

6.  An electrophysiological study of the mechanism of fatigue in multiple sclerosis.

Authors:  G L Sheean; N M Murray; J C Rothwell; D H Miller; A J Thompson
Journal:  Brain       Date:  1997-02       Impact factor: 13.501

7.  German version of the Epworth Sleepiness Scale.

Authors:  K E Bloch; O D Schoch; J N Zhang; E W Russi
Journal:  Respiration       Date:  1999       Impact factor: 3.580

8.  A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group.

Authors: 
Journal:  Can J Neurol Sci       Date:  1987-08       Impact factor: 2.104

9.  Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study.

Authors:  Udo A Zifko; Monika Rupp; Sigrid Schwarz; Harald T Zipko; Eva M Maida
Journal:  J Neurol       Date:  2002-08       Impact factor: 4.849

10.  Fatigue in multiple sclerosis compared with chronic fatigue syndrome: A quantitative assessment.

Authors:  R Djaldetti; I Ziv; A Achiron; E Melamed
Journal:  Neurology       Date:  1996-03       Impact factor: 9.910

View more
  15 in total

1.  Impact of fatigue in Parkinson's disease: the Fatigue Impact Scale for Daily Use (D-FIS).

Authors:  Pablo Martinez-Martin; Maria Jose Catalan; Julian Benito-Leon; Angel Ortega Moreno; Ivana Zamarbide; Esther Cubo; Nadeje van Blercon; Victor Campos Arillo; Margarita Pondal; Gurutz Linazasoro; Fernando Alonso; Pedro García Ruiz; Belen Frades
Journal:  Qual Life Res       Date:  2006-05       Impact factor: 4.147

2.  Validation of the fatigue severity scale in a Swiss cohort.

Authors:  Philipp O Valko; Claudio L Bassetti; Konrad E Bloch; Ulrike Held; Christian R Baumann
Journal:  Sleep       Date:  2008-11       Impact factor: 5.849

Review 3.  Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

4.  Walgreens connected care: impact of managed therapy on adherence to medications used to treat multiple sclerosis and related comorbid conditions.

Authors:  Janeen DuChane; Bobby Clark; Francis Staskon; Rick Miller; Kathleen Love; Ian Duncan
Journal:  Int J MS Care       Date:  2015 Mar-Apr

5.  Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease.

Authors:  K D Kistler; J Molleston; A Unalp; S H Abrams; C Behling; J B Schwimmer
Journal:  Aliment Pharmacol Ther       Date:  2009-10-23       Impact factor: 8.171

Review 6.  Autonomic dysfunction in multiple sclerosis.

Authors:  Carl-Albrecht Haensch; Johannes Jörg
Journal:  J Neurol       Date:  2006-02       Impact factor: 4.849

Review 7.  Pharmacological treatments for fatigue associated with palliative care.

Authors:  Martin Mücke; Henning Cuhls; Vera Peuckmann-Post; Ollie Minton; Patrick Stone; Lukas Radbruch
Journal:  Cochrane Database Syst Rev       Date:  2015-05-30

8.  Comparison of the Psychometric Properties of Three Fatigue Scales in Persian-Speaking Patients with Multiple Sclerosis.

Authors:  Shabnam Behrangrad; Amin Kordi Yoosefinejad
Journal:  Int J MS Care       Date:  2020-02-14

9.  The effect of systemic amantadine sulfate on malondialdehyde and total thiol levels in rat corneas.

Authors:  Züleyha Yalniz-Akkaya; Vildan Fidanci; Aytul Kilinc; Ayse Burcu; Guner O Uney; Firdevs Ornek
Journal:  J Ophthalmic Vis Res       Date:  2014 Jul-Sep

10.  Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis.

Authors:  Tjalf Ziemssen; Josef Hoffman; Rainer Apfel; Simone Kern
Journal:  Health Qual Life Outcomes       Date:  2008-09-05       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.